Cargando…
Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
An increase in COVID-19 immunization coverage has been linked to a decrease in the average case fatality rate. As a result, further research is needed to determine the persistence and duration of vaccine-induced protective antibodies in order to assess the effectiveness of COVID-19 vaccinations. The...
Autores principales: | Devi, Leimapokpam Sumitra, Sardar, Moumita, Sharma, Mukesh, Khandait, Manisha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173867/ https://www.ncbi.nlm.nih.gov/pubmed/35685779 http://dx.doi.org/10.1155/2022/4729844 |
Ejemplares similares
-
Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
por: Sivaramakrishnan, Prakash, et al.
Publicado: (2022) -
Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
por: Singh, Amandeep, et al.
Publicado: (2022) -
Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield) in patients with liver cirrhosis
por: Katiyar, Harshita, et al.
Publicado: (2022) -
Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
por: Goel, Amit, et al.
Publicado: (2022) -
Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers
por: Verma, Alka, et al.
Publicado: (2022)